View in EDS HTML Full Text PDF Full Text

Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability.

Saved in:
Bibliographic Details
Title: Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability.
Authors: Simpson, Seth (AUTHOR), Dominick, Kelli C. (AUTHOR), Erickson, Craig A. (AUTHOR), Lamy, Martine (AUTHOR)
Source: Journal of Autism & Developmental Disorders. May2026, Vol. 56 Issue 5, p2077-2083. 7p.
Subjects: Patient compliance, Disabilities, Bipolar disorder, Patient safety, Controlled release preparations, Body mass index, Data analysis, T-test (Statistics), Autism, Emergency room visits, Antipsychotic agents, Descriptive statistics, Deprescribing, Retrospective studies, Severity of illness index, Schizophrenia, Intellectual disabilities, Injections, Obsessive-compulsive disorder, Drug efficacy, Medical records, Acquisition of data, Statistics, Asperger's syndrome, Drugs, Affect (Psychology), Drug tolerance, Transition to adulthood, Carpal tunnel syndrome, Mental depression
Abstract: This retrospective chart review examines the safety, tolerability and effectiveness of long acting injectable paliperidone palmitate (P-LAI) targeting irritability in twenty-six youth and transition-aged individuals with autism spectrum disorder (ASD) and/or intellectual disability (ID) over a 3-year window. Clinical response was evaluated via prospectively assigned Clinical Global Impressions Severity (CGI-S) and Improvement (CGI-I) scales as well as number of hospital presentations. P-LAI was well tolerated with only 3 patients stopping P-LAI due to side effects. The average duration of P-LAI treatment was 21.1 months. Difficulty with medication compliance was the most common reason for initiating P-LAI. There was a statistically significant improvement in CGI-I, CGI-S and hospital visits and no change in BMI noted. Given the potential difficulty of medication administration in this population, this evidence of safety, tolerability as well as preliminary data supporting effectiveness is an important addition to the literature regarding psychopharmacologic management of irritability in youth with ASD and ID. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Autism & Developmental Disorders is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 193884028
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Simpson%2C+Seth%22">Simpson, Seth</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dominick%2C+Kelli+C%2E%22">Dominick, Kelli C.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Erickson%2C+Craig+A%2E%22">Erickson, Craig A.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lamy%2C+Martine%22">Lamy, Martine</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Journal+of+Autism+%26+Developmental+Disorders%22">Journal of Autism & Developmental Disorders</searchLink>. May2026, Vol. 56 Issue 5, p2077-2083. 7p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Patient+compliance%22">Patient compliance</searchLink><br /><searchLink fieldCode="DE" term="%22Disabilities%22">Disabilities</searchLink><br /><searchLink fieldCode="DE" term="%22Bipolar+disorder%22">Bipolar disorder</searchLink><br /><searchLink fieldCode="DE" term="%22Patient+safety%22">Patient safety</searchLink><br /><searchLink fieldCode="DE" term="%22Controlled+release+preparations%22">Controlled release preparations</searchLink><br /><searchLink fieldCode="DE" term="%22Body+mass+index%22">Body mass index</searchLink><br /><searchLink fieldCode="DE" term="%22Data+analysis%22">Data analysis</searchLink><br /><searchLink fieldCode="DE" term="%22T-test+%28Statistics%29%22">T-test (Statistics)</searchLink><br /><searchLink fieldCode="DE" term="%22Autism%22">Autism</searchLink><br /><searchLink fieldCode="DE" term="%22Emergency+room+visits%22">Emergency room visits</searchLink><br /><searchLink fieldCode="DE" term="%22Antipsychotic+agents%22">Antipsychotic agents</searchLink><br /><searchLink fieldCode="DE" term="%22Descriptive+statistics%22">Descriptive statistics</searchLink><br /><searchLink fieldCode="DE" term="%22Deprescribing%22">Deprescribing</searchLink><br /><searchLink fieldCode="DE" term="%22Retrospective+studies%22">Retrospective studies</searchLink><br /><searchLink fieldCode="DE" term="%22Severity+of+illness+index%22">Severity of illness index</searchLink><br /><searchLink fieldCode="DE" term="%22Schizophrenia%22">Schizophrenia</searchLink><br /><searchLink fieldCode="DE" term="%22Intellectual+disabilities%22">Intellectual disabilities</searchLink><br /><searchLink fieldCode="DE" term="%22Injections%22">Injections</searchLink><br /><searchLink fieldCode="DE" term="%22Obsessive-compulsive+disorder%22">Obsessive-compulsive disorder</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+efficacy%22">Drug efficacy</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+records%22">Medical records</searchLink><br /><searchLink fieldCode="DE" term="%22Acquisition+of+data%22">Acquisition of data</searchLink><br /><searchLink fieldCode="DE" term="%22Statistics%22">Statistics</searchLink><br /><searchLink fieldCode="DE" term="%22Asperger's+syndrome%22">Asperger's syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22Drugs%22">Drugs</searchLink><br /><searchLink fieldCode="DE" term="%22Affect+%28Psychology%29%22">Affect (Psychology)</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+tolerance%22">Drug tolerance</searchLink><br /><searchLink fieldCode="DE" term="%22Transition+to+adulthood%22">Transition to adulthood</searchLink><br /><searchLink fieldCode="DE" term="%22Carpal+tunnel+syndrome%22">Carpal tunnel syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22Mental+depression%22">Mental depression</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: This retrospective chart review examines the safety, tolerability and effectiveness of long acting injectable paliperidone palmitate (P-LAI) targeting irritability in twenty-six youth and transition-aged individuals with autism spectrum disorder (ASD) and/or intellectual disability (ID) over a 3-year window. Clinical response was evaluated via prospectively assigned Clinical Global Impressions Severity (CGI-S) and Improvement (CGI-I) scales as well as number of hospital presentations. P-LAI was well tolerated with only 3 patients stopping P-LAI due to side effects. The average duration of P-LAI treatment was 21.1 months. Difficulty with medication compliance was the most common reason for initiating P-LAI. There was a statistically significant improvement in CGI-I, CGI-S and hospital visits and no change in BMI noted. Given the potential difficulty of medication administration in this population, this evidence of safety, tolerability as well as preliminary data supporting effectiveness is an important addition to the literature regarding psychopharmacologic management of irritability in youth with ASD and ID. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Journal of Autism & Developmental Disorders is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=193884028
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10803-024-06372-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 2077
    Subjects:
      – SubjectFull: Patient compliance
        Type: general
      – SubjectFull: Disabilities
        Type: general
      – SubjectFull: Bipolar disorder
        Type: general
      – SubjectFull: Patient safety
        Type: general
      – SubjectFull: Controlled release preparations
        Type: general
      – SubjectFull: Body mass index
        Type: general
      – SubjectFull: Data analysis
        Type: general
      – SubjectFull: T-test (Statistics)
        Type: general
      – SubjectFull: Autism
        Type: general
      – SubjectFull: Emergency room visits
        Type: general
      – SubjectFull: Antipsychotic agents
        Type: general
      – SubjectFull: Descriptive statistics
        Type: general
      – SubjectFull: Deprescribing
        Type: general
      – SubjectFull: Retrospective studies
        Type: general
      – SubjectFull: Severity of illness index
        Type: general
      – SubjectFull: Schizophrenia
        Type: general
      – SubjectFull: Intellectual disabilities
        Type: general
      – SubjectFull: Injections
        Type: general
      – SubjectFull: Obsessive-compulsive disorder
        Type: general
      – SubjectFull: Drug efficacy
        Type: general
      – SubjectFull: Medical records
        Type: general
      – SubjectFull: Acquisition of data
        Type: general
      – SubjectFull: Statistics
        Type: general
      – SubjectFull: Asperger's syndrome
        Type: general
      – SubjectFull: Drugs
        Type: general
      – SubjectFull: Affect (Psychology)
        Type: general
      – SubjectFull: Drug tolerance
        Type: general
      – SubjectFull: Transition to adulthood
        Type: general
      – SubjectFull: Carpal tunnel syndrome
        Type: general
      – SubjectFull: Mental depression
        Type: general
    Titles:
      – TitleFull: Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Simpson, Seth
      – PersonEntity:
          Name:
            NameFull: Dominick, Kelli C.
      – PersonEntity:
          Name:
            NameFull: Erickson, Craig A.
      – PersonEntity:
          Name:
            NameFull: Lamy, Martine
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: May2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 01623257
          Numbering:
            – Type: volume
              Value: 56
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Journal of Autism & Developmental Disorders
              Type: main
ResultId 1